Amiloidose Genetica

Opinion

... in response to Alnylam Pharmaceuticals presents new data on ALN-TTR01 RNAi therapeutic at amyloidosis symposium

Amiloidose Genetica

Julio Andrade Janot says:

November 30, 2011 at 7:24 AM

Dear Sirs.
I was very hopeful when I read the report on the ALN-TTR01 RNAi efficiently developed by this company because I am the bearer of Amyloidosis genetics and plenty of time to try a treatment that leads me to cure this disease highly lethal (5 to 10 years). In the near past October I sent a mail (email) requesting an opinion of you and up to now received no reply. I want to reiterate the request because the state already that I am deficient in the tetraplegia and no drug specifically for the stabilization of the disease. I offer myself if necessary to serve as a guinea pig for drug development or go to the United States for consultation.

0 0

Reply

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

Post

Hi, I'm Azthena, you can trust me to find commercial scientific answers from News-Medical.net.

To start a conversation, please log into your AZoProfile account first, or create a new account.

Registered members can chat with Azthena, request quotations, download pdf's, brochures and subscribe to our related newsletter content.

A few things you need to know before we start. Please read and accept to continue.

Use of “Azthena” is subject to the terms and conditions of use as set out by OpenAI.
Content provided on any AZoNetwork sites are subject to the site Terms & Conditions and Privacy Policy.
Large Language Models can make mistakes. Consider checking important information.

I understand, and agree to receive occasional emails about Azthena such as usage tips and new feature announcements.

Please check the box above to proceed.

Great. Ask your question.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.